NCT01089101 2026-03-18
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT02407405 2026-03-05
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01362803 2026-03-02
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT05101148 2026-02-23
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
Phase 1 Active not recruiting
NCT04590235 2026-01-30
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT04924608 2026-01-12
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT05309668 2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2 Active not recruiting